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Abstract
Introduction
• Systemic thrombolysis is standard, first-line treatment for a            
patient presenting with hemodynamically unstable pulmonary 
embolism, but data from randomized trials using catheter directed 
techniques is gaining attention as a viable option for patients who 
have contraindications to high-dose systemic thrombolysis
Research Questions
Literature Review
Applicability to Clinical 
Practice
• The ELOPE (Evaluation of Long-term Outcomes after PE) cohort 
study provided new information on prognosis following 
pulmonary embolism ( Kahn et al., 2017). 
• Data provided by Kahn et al. (2014) did show chronic 
thromboembolic pulmonary hypertension was found to range 
from 1 to 4% with a poor prognosis and a median survival of 12-
24 months. 
• Improvement in obstruction, perfusion, Miller indexes, and 
systolic pulmonary artery pressure before and after rheolytic 
thrombectomy according to hemodynamic compromise (i.e., 
shock, red bars; hypotension, green bars; right ventricular 
dysfunction, blue bars) Chechi et al. (2009).
Discussion
• As the first line treatment for hemodynamically unstable patients 
presenting with pulmonary embolism, systemic thrombolysis is 
well tolerated and efficacious; however, it may be contraindicated 
in patients with prior intracranial hemorrhage, cerebral vascular 
lesions, malignancy, active bleeding, bleeding diathesis or in 
patients older than 65. 
• Systemic thrombolytics remains the gold standard for treatment 
of massive PE for patients without contraindications.
• Catheter directed therapies allow for both low dose intraclot
thrombolytics and mechanical thrombectomy and may prove 
beneficial for the long-term sequela related to massive thrombus. 
• Chronic thromboembolic pulmonary hypertension can be found in 
a small percentage of patients post pulmonary embolism which 
carries a poor prognosis and although the clinical significance of 
residual pulmonary vascular abnormalities continues to be poorly 
understood, the literature review determined that patients may not 
do well long term once diagnosed and treated with thrombolytics
(Kahn et al., 2014). 
• Chronic thromboembolic pulmonary hypertension was found to 
range from 1 to 4% with a poor prognosis and a median survival 
of 12-24 months (Kahn et al., 2017).
• The question of what is the best treatment option for patients 
presenting with hemodynamically unstable massive pulmonary 
embolism was not definitively answered in my review of the 
literature and shows that further prospective research, comparing 
systemic thrombolytic therapy to catheter directed treatments to 
include long-term outcomes, is indicated.   
 Acute massive pulmonary embolism is characterized by 
obstruction of the pulmonary arterial tree that exceeds 50% of the 
cross-sectional area causing acute and severe cardiopulmonary 
failure from right ventricular overload.
• Systemic thrombolytic therapy is recommended as standard, first-
line treatment in patients with massive pulmonary embolism 
unless contraindicated and catheter directed therapies, including 
low dose thrombolytic administration directly into thrombus and 
mechanical thrombectomy can be adjunctive or used as an 
alternative to systemic treatments. 
• This literature review researched articles looking at both systemic 
thrombolysis and endovascular techniques for the treatment of 
acute massive pulmonary embolism with an emphasis on long 
term clinical outcomes. 
• Study results demonstrated the efficacy and safety of systemic 
thrombolysis and catheter directed therapies as well as adverse 
effects; however, further randomized trials are needed, as 
acknowledged by many of the authors included in this paper, 
comparing both treatment options for hemodynamically unstable 
patients with emphasis on long term sequalae. 
• In patients presenting with acute massive pulmonary embolism, 
how does the use of systemic thrombolytics compare in efficacy 
and safety over catheter directed therapies? 
• Is there improvement in quality of life, dyspnea, and functional 
capacity with catheter directed thrombolysis and thrombectomy 
compared to systemic thrombolysis?
Pathology of Pulmonary Embolism
• Thrombus occurs when there is a disruption in the mechanisms 
between blood coagulation and anticoagulation, and PE can 
follow when thrombus from a deep vein thrombosis (DVT) 
breaks off and travels to the pulmonary circulation, although non-
thrombotic material like fat, tumor or air can also be the source 
(Giordano, Jansson, Young, Hogan, & Kabrhel, 2017). 
• If the DVT forms in a large vessel, it is more likely to dislodge 
and embolize the pulmonary artery occluding some degree of the 
vasculature. 
• Large thrombi can straddle the bifurcation or obstruct the entire 
pulmonary outflow tract, increasing the strain on the right heart 
and leading to severe hypotension and death (Giordano, Jansson, 
Young, Hogan, & Kabrhel, 2017).
Treatment Options for Pulmonary Embolism
• Depends on the hemodynamic stability of the patient and the clot 
burden. 
• Therapy consists of anticoagulation, systemic thrombolytics and 
endovascular therapies including mechanical thrombectomy and 
intraclot thrombolysis (Chechi et al., 2009).
• Systemic thrombolysis is standard, first-line treatment with low 
risk for major hemorrhage in selected patients. 
• Catheter directed therapies, including low dose thrombolytic 
administration directly into thrombus and mechanical 
thrombectomy can be adjunctive or used as an alternative to 
systemic treatments. 
Safety of Systemic and Endovascular Therapy
• Major and minor bleeding remain a concern when using 
thrombolytics even though evidence suggest these agents dissolve 
clots more rapidly than heparin and reduce the death rate 
associated with PE (Hao, Dong, Yue, & Liu, 2015). 
• Systemic thrombolysis demonstrates an increased risk of 
hemorrhage when compared to catheter directed intraclot lytics 
(Kuo et al., 2009). 
• A meta-analysis conducted by Bloomer et al. (2017), 
demonstrated low bleeding complications with CDT
Long Term Sequela
• When treating hemodynamically unstable patients presenting with 
pulmonary embolism, it’s important to consider not only the 
immediate threat, but also long term sequela like quality of life 
(Kahn et al., 2017). 
• Hemodynamically unstable patients may not do well once 
diagnosed and treated for massive pulmonary embolism (Kahn et 
al., 2014). 
• Diagnosis of PE uses a combination of techniques including a D 
dimer, CTA and scoring systems like Geneva, Wells, and Miniati
and studies have demonstrated a low probability of pulmonary 
embolism if the D-dimer is normal and the scoring system used 
shows a low probability. This is important data for clinicians 
working in rural areas where access to CTA might not be available. 
• The efficacy and safety of both systemic and catheter directed 
therapies appears comparable depending on which study you read, 
especially looking at short term outcomes. 
• Several studies have looked at long-term sequela post pulmonary 
embolism and the role residual thrombus plays in quality of life 
measures. The clinical significance of residual pulmonary vascular 
abnormalities continues to be poorly understood but there is 
agreement that these patients may not do well long-term due to 
chronic thromboembolic pulmonary hypertension. 
.
Statement of the Problem
• Deciding on a treatment plan for a patient presenting with an 
acute massive pulmonary embolism can be challenging for some 
clinicians. Systemic thrombolytic therapy continues to be 
standard, first-line therapy, but new technologies using catheter 
directed techniques with a combination of thrombectomy and 
intraclot thrombolysis are demonstrating safety and efficacy and 
are gaining support in the medical community. 
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